Variations of Plasmin in the Hemorrhagic Blood Diseases

Mikata, Ittaku; Hasegawa, M.; Igarashi, Tadahira; Shirakura, N; Hoshida, Masahiro; Toyama, Keisuke

doi:10.2302/kjm.8.279

Cited by 14 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The identification of lysine-binding sites in plasminogen originated from the work of Nagasawa and his colleagues in the Laboratories of Mitsubishi Chemical Company, who filed a patent in 1953. They and others searched for compounds that inhibited plasmin activity and identified epsilon-aminocaproic acid (EACA) as an inhibitor [ 43 ]. Characterization of the activity of this inhibitor revealed that EACA directly inhibited the activation of plasminogen [ 44 ].…”

Section: Role Of the Carboxyl-terminal Lysine In Plasminogen Bindingmentioning

confidence: 99%

The ANXA2/S100A10 Complex—Regulation of the Oncogenic Plasminogen Receptor

2021

View full text Add to dashboard Cite

The generation of the serine protease plasmin is initiated by the binding of its zymogenic precursor, plasminogen, to cell surface receptors. The proteolytic activity of plasmin, generated at the cell surface, plays a crucial role in several physiological processes, including fibrinolysis, angiogenesis, wound healing, and the invasion of cells through both the basement membrane and extracellular matrix. The seminal observation by Albert Fischer that cancer cells, but not normal cells in culture, produce large amounts of plasmin formed the basis of current-day observations that plasmin generation can be hijacked by cancer cells to allow tumor development, progression, and metastasis. Thus, the cell surface plasminogen-binding receptor proteins are critical to generating plasmin proteolytic activity at the cell surface. This review focuses on one of the twelve well-described plasminogen receptors, S100A10, which, when in complex with its regulatory partner, annexin A2 (ANXA2), forms the ANXA2/S100A10 heterotetrameric complex referred to as AIIt. We present the theme that AIIt is the quintessential cellular plasminogen receptor since it regulates the formation and the destruction of plasmin. We also introduce the term oncogenic plasminogen receptor to define those plasminogen receptors directly activated during cancer progression. We then discuss the research establishing AIIt as an oncogenic plasminogen receptor-regulated during EMT and activated by oncogenes such as SRC, RAS, HIF1α, and PML-RAR and epigenetically by DNA methylation. We further discuss the evidence derived from animal models supporting the role of S100A10 in tumor progression and oncogenesis. Lastly, we describe the potential of S100A10 as a biomarker for cancer diagnosis and prognosis.

show abstract

Section: Role Of the Carboxyl-terminal Lysine In Plasminogen Bindingmentioning

confidence: 99%

The ANXA2/S100A10 Complex—Regulation of the Oncogenic Plasminogen Receptor

2021

View full text Add to dashboard Cite

show abstract

“…Άντιινωδολυτικά φάρμακα έχρησιμοποιήθησαν είς ασθενείς μέ επαναλαμβα νόμενος ρινορραγίας, όπως τό Ε-άμινοκαπροϊκόν οξύ (ΕΑΚΑ), τό παραμινομεθυλβενζοϊκόν οξύ (PAMPA) και τρανεξαμινικόν οξύ (ΑΜΚΑ). Ταύτα έχρησι μοποιήθησαν κυρίως άπό τον ΜΙΚΑΤΑ τό 1959 καί τους HOLFMAN και MAY τό 1967 12 . Ό SAUNDERS 1964 έχρησιμοποίησεν τήν μέθοδον τής μεταμοσχεύσεως δέρματος κατόπιν αφαιρέσεως του αίμορραγοϋντος ρινικού βλεννογόνου έπί περιπτώσεων κληρονομικής τελαγγειεκτασΐας ή νόσου τών RENDU-OSLER-WEBER , 3 .…”

Section: ιστορικη ανασκοπησιςunclassified